Crossmark

Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial

Crossref DOI link: https://doi.org/10.1186/s13063-018-2560-4

Published Online: 2018-03-09

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Defer, Gilles

Le Caignec, Florian

Fedrizzi, Sophie

Montastruc, François

Chevanne, Damien

Parienti, Jean-Jacques

Peyro-Saint-Paul, Laure
Funding

Funding for this research was provided by:

Agence Régionale de Santé de Normandie

RBN-SEP Association
License Information

Text and Data Mining valid from 2018-03-09
More Information

Article History

Received: 27 October 2017

Accepted: 26 February 2018

First Online: 9 March 2018

Authors' information

: Not applicable

: This study was approved by the Ethics Committee of Nord-Ouest III with approval number 2016–42. Informed consent will be obtained from all participants.

: The authors consent to publication of this article.

: The funders had no involvement in the collection, management, analysis and interpretation of data. The authors and investigators declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below